Imatinib + MTC in Relapsed / Refractory Acute Myeloid Leukemia (AML)
NCT ID: NCT00744081
Last Updated: 2023-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
130 participants
INTERVENTIONAL
2004-07-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
NCT00327262
PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
NCT00088231
Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia
NCT00390897
Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia
NCT00079313
CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT00955916
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glivec
Mitoxantrone
Topotecan
AraC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* First relapse after a safe previous diagnosis of de novo or secondary AML
* Age \> 18 years
* Serum bilirubin \< 2.0 mg/dl
* Serum creatinine \< 1.5 times the normal value or a creatinine clearance \> 60 ml/min
* ECG and heart echography prior to start of therapy without severe findings
* Overall condition \< 2 according to ECOG criteria
* Life expectancy \> 6 weeks
* Written informed consent by patients with full legal capacity
Exclusion Criteria
* Active secondary neoplasia (exception: adequately treated basalioma or epidermoid cancer and cervical carcinoma)
* Known hypersensitivity to topoisomerase-I inhibitors
* Overall condition \> 2 according to ECOG criteria
* Pregnant/breast feeding women
* Serious intercurrent infections
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Goethe University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lothar Bergmann
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lothar Bergmann, MD, PhD
Role: STUDY_CHAIR
University Hospital of Frankfurt, Medical Dept. II
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Frankfurt, Medical Dept. II
Frankfurt, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
(German Leukemia Trial Registry)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMLSG-R1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.